BCMA / CD123 / CD22 Report Package: Hot targets for Empowered Antibody and Cell Therapy Technologies - Research and Markets

DUBLIN, Dec 21, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Report Package: Hot targets for Empowered Antibody and Cell Therapy Technologies" report to their offering.

This package contains three reports analyzing:

- BCMA

- CD123

- CD22

As versatile and hot targets for the successful application of empowered antibody and cell technologies, including:

- Fc-Engineered Antibodies;

- Radioimmunotherapy;

- Immunotoxins;

- Antibody-Drug Conjugates;

- T-Cell Redirecting Bispecific Antibodies;

- Chimeric Antigen Receptor (CAR) T-Cells.

The reports describe and discuss:

- Target background, scientific rationale & expression profiles;

- Preclinical proof-of-concept;

- Clinical experience;

- Competitive landscape;

- Drug or cell therapy profiles;

- Company profiles.

Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices:

B-Cell Maturation Antigen (BCMA): Hot target for Emerging Treatment Modalities

CD123: A Paradigmatic Target for Immunotherapeutic Treatment Modalities

CD22: A Suitable Antigen for Targeted Payload Delivery by Immunotherapeutics

Detailed report descriptions and tables of from the reports can be found on the respective product pages listed in the "Also Available" section below.

Key Topics Covered:

Report 1: B-Cell Maturation Antigen (BCMA): Hot target for Emerging Treatment Modalities

1. Target Background

2. Target Antigen Expression Profile

3. Preclinical Proof-of-Concept

4. Clinical Indications & Treatment Options

5. Clinical Experience with BCMA-Targeted Treatment Modalities

6. Treatment Modalities & Competitive Landscape

- Drug & Cell Therapy Candidate Profiles

- CAR T-Cells

- Antibody-Drug Conjugate (ADC)

- T-Cell Redirecting Antibodies

7. Company Profiles

8. References

Report 2: CD123: A Paradigmatic Target for Immunotherapeutic Treatment Modalities

1. Target Background & Scientific Rationale

2. Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics

3. Clinical Experience with CD123-Targeted Treatment Modalities

4. Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics

5. Competitive Landscape

6. Profiles of Anti-CD123 Immunotherapeutics:

- Immunotoxins

- Naked Antibody - Fc-Engineered Antibodies - Antibody-Drug Conjugates - T-Cell Redirecting Bispecific Antibodies - Anti-CD123 CAR T-Cells

7. Company Profiles

8. References

9. ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics

Report 3: CD22: A Suitable Antigen for Targeted Payload Delivery by Immunotherapeutics

1. Target Background & Scientific Rationale

2. Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics

3. Competitive Landscape

4. Profiles of Anti-CD22 Immunotherapeutics

- Naked antibodies;

- Radioimmunotherapy (RIT);

- Immunotoxins (IT);

- Antibody-Dug Conjugates (ADC); and

- Chimeric Antigen Receptor (CAR) T-Cells.

5. Profiles of Companies with CD22-Targeted Immunotherapeutics

6. References

7. ADDENDUM: Competitor Analysis of CD22-Targeted Immunotherapeutics

For more information about this report visit http://www.researchandmarkets.com/research/g8ctjp/report_package

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[e-mail]

For E.S.T Office Hours Call [phone]

For U.S./CAN Toll Free Call [phone]

For GMT Office Hours Call [phone]

U.S. Fax: [phone]

Fax (outside U.S.): [phone]